• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rhabdomyosarcoma - Pipeline Review, H2 2012 Product Image

Rhabdomyosarcoma - Pipeline Review, H2 2012

  • Published: December 2012
  • 91 pages
  • Global Markets Direct

Rhabdomyosarcoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Rhabdomyosarcoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rhabdomyosarcoma.
- A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Rhabdomyosarcoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Rhabdomyosarcoma 10
Rhabdomyosarcoma Therapeutics under Development by Companies 12
Rhabdomyosarcoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Rhabdomyosarcoma Therapeutics – Products under Development by Companies 19
Rhabdomyosarcoma Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Rhabdomyosarcoma Therapeutics Development 22
F. Hoffmann-La Roche Ltd. 22
Eli Lilly and Company 23
Oncolytics Biotech Inc. 24
Vaccinex, Inc. 25
Neotropix, Inc. 26
Rhabdomyosarcoma – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
cixutumumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NTX-010 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Seneca Valley Virus-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dactinomycin + Filgrastim + Carboplatin + Cyclophosphamide + Doxorubicin + Epirubicin + Etoposide + Ifosfamide + Vincristine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Reolysin + Cisplatin + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ifosfamide + Doxorubicin Hydrochloride + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dasatinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Trofosfamide + Idarubicin + Etoposide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
sorafenib tosylate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Topotecan + Carboplatin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Doxorubicin + Cyclophosphamide + Carboplatin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 53
Therapeutic Autologous Dendritic Cells + Indinavir Sulfate + Stem Cell Transplantation - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 55
Filgrastim SD/01 + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate + Mesna - Drug Profile 56
Product Description 56
Mechanism of Action 57
R&D Progress 58
everolimus - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Vinorelbine + Cyclophosphamide + Bevacizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Vinorelbine + Cyclophosphamide + Torisel - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LY-2940680 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VX-70 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Avastin + Standard Chemotherapy - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vinorelbine + Topotecan - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Neuroblastoma Vaccine + Decitabine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Vincristine + Irinotecan + Temozolomide - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Avastin + Cyclophosphamide + Vinorelbine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
EF-2 Peptide + IL-2 + Autologous T-Cell Transplantation - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
EF-2 Peptide + IL-2 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PXFK Peptide + IL-2 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PXFK Peptide + IL-2 + Autologous T cell Transplantation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 78
E7 Peptide + IL-2 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
E7 Peptide + IL-2 + Autologous T Cell Transplantation - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Vincristine + Dactinomycin + Cyclophosphamide - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Gemcitabine + Pazopanib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Rhabdomyosarcoma Therapeutics – Drug Profile Updates 85
Rhabdomyosarcoma Therapeutics – Discontinued Products 87
Rhabdomyosarcoma Therapeutics - Dormant Products 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91

List of Tables
Number of Products Under Development for Rhabdomyosarcoma, H2 2012 10
Products under Development for Rhabdomyosarcoma – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
F. Hoffmann-La Roche Ltd., H2 2012 22
Eli Lilly and Company, H2 2012 23
Oncolytics Biotech Inc., H2 2012 24
Vaccinex, Inc., H2 2012 25
Neotropix, Inc., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Rhabdomyosarcoma Therapeutics – Drug Profile Updates 85
Rhabdomyosarcoma Therapeutics – Discontinued Products 87
Rhabdomyosarcoma Therapeutics – Dormant Products 88
Rhabdomyosarcoma Therapeutics – Dormant Products (Contd..1) 89

List of Figures
Number of Products under Development for Rhabdomyosarcoma, H2 2012 10
Products under Development for Rhabdomyosarcoma – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos